作者
Xiaomei Li,Puyi He,Yanmei Gu,Rong Cui,Long Ma,Xuemei Li,Yumin Li
摘要
Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide. Claudin 3 (CLDN3), a tight junction protein aberrantly expressed in multiple malignancies, has been implicated in tumor progression. However, its functional significance and therapeutic relevance in GC remain incompletely defined. Therefore, we systematically evaluated the functional role and underlying mechanisms of CLDN3 in GC using clinical cohort analysis, in vitro and in vivo experiments, immune co-culture systems, and transcriptomic and proteomic analyses. Using hybridoma technology, we also generated a monoclonal antibody against CLDN3 and assessed its antitumor efficacy, both as monotherapy and in combination with anti-PD-1 blockade, in vitro and in vivo . CLDN3 was upregulated in GC tissues and was associated with poor prognosis, aggressive clinicopathological features, and decreased intratumoral CD8 + T-cell infiltration. Mechanistically, CLDN3 activated the NF-κB pathway by promoting p65 phosphorylation and nuclear translocation, thereby enhancing CXCL1 transcription and consequently driving GC cell proliferation, migration, and invasion. Furthermore, CLDN3 upregulated PD-L1 expression in a CXCL1-dependent manner, leading to decreased CD8 + T-cell infiltration and attenuated CD8 + T-cell-mediated tumor cell killing. Notably, the anti-CLDN3 monoclonal antibody demonstrated high binding affinity and specificity, significantly suppressed tumor growth and metastasis in vivo , and enhanced the antitumor efficacy of anti-PD-1 blockade, accompanied by increased CD8 + T-cell infiltration. Collectively, these findings indicate that CLDN3 promotes GC progression and immune evasion by activating the NF-κB/p65–CXCL1–PD-L1 signaling axis, and CLDN3 blockade combined with PD-1 inhibition may represent a promising therapeutic strategy for GC.